This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBDC Apotheca Biosciences (CBDC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Apotheca Biosciences Stock (NASDAQ:CBDC) 30 days 90 days 365 days Advanced Chart Get Apotheca Biosciences alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range$0.00▼$0.0852-Week Range$0.00▼$0.31VolumeN/AAverage Volume21,204 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewApotheca Biosciences, Inc. develops cutting-edge medical products, nutraceuticals, formulations, and delivery technologies for the healthcare and consumer care industry in the United States. The company's products include transdermal, sublingual, and nasal delivery devices for dosing of cannabinoids. It also provides CBD pain cream, gel capsules, patches, and sleep tablets; and Promed, anti-aging and cosmetic products. The company was incorporated in 2014 and is based in Saint Petersburg, Florida.Read More… Receive CBDC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apotheca Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CBDC Stock News HeadlinesApotheca Biosciences IncFebruary 18, 2025 | thestreet.comThe Digital Dollar Project Publishes a Risk Framework for Consideration of a U.S. CBDCJuly 4, 2023 | finance.yahoo.comElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly becoming one of the most profitable stories of the year.June 5, 2025 | True Market Insiders (Ad)The Digital Currency Monetary Authority (DCMA) Launches an International Central Bank Digital Currency (CBDC)April 16, 2023 | finance.yahoo.comFlorida Governor Ron DeSantis proposes banning a digital currency from the Fed, arguing it will stifle innovation and promote surveillanceMarch 24, 2023 | markets.businessinsider.comWe're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash WiselyFebruary 27, 2023 | finance.yahoo.comJapan Joins the CBDC Race, Will Conduct Tests in AprilFebruary 19, 2023 | 247wallst.comHM Treasury Seeking Head of CBDC as UK Moves Closer to the Digital PoundJanuary 27, 2023 | 247wallst.comSee More Headlines CBDC Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Apotheca Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apotheca Biosciences investors own include SoFi Technologies (SOFI), Andersons (ANDE), British American Tobacco (BTI), Copa (CPA), Cronos Group (CRON), FREYR Battery (FREY) and Kraft Heinz (KHC). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CBDC CIK1632053 Webwww.apothecabiosciences.com Phone727-228-3994FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:CBDC) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apotheca Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apotheca Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
